Lebrikizumab Phase 2b in AD

Key messages

• Atopic dermatitis is a common condition with a complex pathophysiology.
• New therapies target the underlying inflammation to deliver symptom relief.
• Lebrikizumab significantly improved clinical efficacy and patient-reported outcomes in moderate-to severe atopic dermatitis compared with placebo.
• Lebrikizumab was well tolerated and showed an acceptable short-term safety profile.